Overview

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

Status:
Active, not recruiting
Trial end date:
2025-06-20
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to observe the efficacy and safety of Serplulimab monotherapy as a neoadjuvant treatment for TPS ≥ 50% non-small cell lung cancer (NSCLC).
Phase:
Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital